US20200337999A1 - Dry powder ketamine composition for use in the treatment of depression by pulmonary administration - Google Patents

Dry powder ketamine composition for use in the treatment of depression by pulmonary administration Download PDF

Info

Publication number
US20200337999A1
US20200337999A1 US16/958,965 US201816958965A US2020337999A1 US 20200337999 A1 US20200337999 A1 US 20200337999A1 US 201816958965 A US201816958965 A US 201816958965A US 2020337999 A1 US2020337999 A1 US 2020337999A1
Authority
US
United States
Prior art keywords
ketamine
composition
esketamine
dose
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US16/958,965
Other languages
English (en)
Inventor
Maciej Wieczorek
Ewa TRATKIEWICZ
Przemyslaw PERKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celon Pharma SA
Original Assignee
Celon Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma SA filed Critical Celon Pharma SA
Assigned to CELON PHARMA S.A. reassignment CELON PHARMA S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PERKO, Przemyslaw, TRATKIEWICZ, Ewa, WIECZOREK, MACIEJ
Publication of US20200337999A1 publication Critical patent/US20200337999A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to a composition comprising ketamine, in particular dry powder formulation for use in a method of treatment of depression by pulmonary administration.
  • Depression especially major depressive disorder, bipolar disorder and treatment-resistant depression (TRD) is a serious problem in a modern society.
  • Many treatment options have been developed for treating depression, including monotherapy or combination therapy in a convenient for patients oral administration regimen.
  • monotherapy or combination therapy in a convenient for patients oral administration regimen.
  • at present the only real choice in such severe cases can be electroshocks.
  • Ketamine is a known anesthetic and analgetic, used for anesthesia and in the treatment of chronic pain.
  • Ketamine is a chiral compound and can exist as a racemate and as S-enantiomer (known as esketamine) or R-enantiomer (known as arketamine).
  • Ketamine can form a pharmaceutically acceptable salts and in pharmaceutical applications is generally used as preferred hydrochloride salt.
  • the optical rotation of an enantiomer varies between ketamine and its salts. For example, while esketamine free base is dextrarotatory S-(+), esketamine hydrochloride is levorotatory S-( ⁇ ).
  • Treatment-resistant depression is a term used in clinical psychiatry to describe cases of major depressive disorder that do not respond adequately to appropriate courses of at least two antidepressants in a suitable dose for a suitable time.
  • ketamine and esketamine Data collected up to now show exceptional properties of ketamine and esketamine.
  • the effect is very quick (after 2-3 hours from administration) and relatively long-lasting—a few days after single dose of a medicament.
  • the rapidity of the clinical effect is surprisingly high and unexpected, since the effect of antidepressants present on the market appears after at least two weeks, even three to four weeks of day-to-day administration. Therefore, ketamine or esketamine could be used as a drug of first choice in patients with major depression with enhanced suicide risk that are resistant to existing oral antidepressants.
  • the scale of the effect is also very high; about 2 ⁇ 3 of the patients with treatment-resistant depression is responsive to ketamine treatment.
  • Literature describes many examples of ketamine pharmacokinetics depending on the administration route.
  • Administration route with currently expected minimum level of metabolites is an intravenous one. After intravenous infusion of racemic ketamine at 0.5 mg/kg for 40 minutes, the parent drug maintains its systemic concentration about 200 ng/ml for about 40 minutes, afterwards the concentration falls down quickly with a half-period below 2 hours. Simultaneously, norketamine reaches its maximum concentration at the level of 10-20% of ketamine concentration. The percentage of area-under-curve (AUC) norketamine to ketamine is about 20-40%.
  • AUC area-under-curve
  • Oral administration is the administration route, after which maximum concentration of metabolites is expected. However, after oral administration the drug rapidly undergoes metabolism to norketamine. Norketamine level is equal to 500-1000% of ketamine level. Area-under-curve (AUC) for norketamine is even higher, exceeding 1000%.
  • AUC Area-under-curve
  • US2007/0287753A1 discloses the use of ketamine for treating treatment-resistant or refractory depression.
  • the only formulation tested is the intravenous infusion, and transdermal administration is contemplated as well.
  • Intranasal administration is only generally described, including intranasal administration of a dry powder aerosol formulation comprising finely divided powder of ketamine, a dispersant and bulking agent.
  • ketamine to oropharyngeal area significant amounts of ketamine will be swallowed by a patient by oral route and can undergo systemic metabolism to norketamine to cause undesired side effects.
  • DE102007009888 discloses the use of S-ketamine in the treatment of depression, in the dosage of 0.3 to 1.0 mg/kg. Although all possible administration routes are generally mentioned, the only formulation tested is intravenous infusion, mentioned as the preferred one.
  • WO2013/138322 discloses the use of esketamine in the treatment of treatment-refractory or treatment-resistant depression. Test for efficacy of esketamine was described in prophetic example with esketamine intravenous infusion.
  • WO2014/143646 and WO2014/152196 disclose pharmaceutical composition of esketamine in the form of the aqueous formulation of esketamine hydrochloride, preferably for nasal administration, for use in the treatment of treatment-refractory or treatment-resistant depression.
  • Mucoadhesive oral forms of esketamine and pharmacokinetics of esketamine after oral, intranasal and intravenous administration are described in WO2014/020155.
  • ketamine formulation that is both highly effective as well as convenient and easy to everyday self-administration by the patient including self-administration on out-patient basis to ensure high patient compliance.
  • a formulation should first of all deliver therapeutic ketamine dose to the blood, should be characterized with high effectiveness, including rapid therapeutic effect and low risk of undesired effects, such as DP, due to precise dosing.
  • Such a formulation should allow only a minimum level of systemic first-pass metabolites such as norketamine and hydroxylated metabolites, especially assure acceptable (es)ketamine to (es)norketamine ratio, both in view of avoiding reduction of ketamine level actually administered and unwanted metabolites effects.
  • the target was to achieve similar ketamine plasma concentration and hence similar antidepressant effect as that by Sing et al. with intravenous infusion of 0.20 mg/kg lasting 40 minutes using route of administration more convenient for a patient and producing less adverse effects.
  • the above problems have been solved by the present invention that provides a high-dose and stable dry powder ketamine pharmaceutical composition for use in a method of treatment of depression by pulmonary administration route in a reliable, reproducible and convenient manner.
  • the invention provides a dry powder pharmaceutical composition comprising ketamine or a pharmaceutically acceptable salt thereof as a medicine for use in a method of treatment of depression by pulmonary administration.
  • the invention provides ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression, wherein ketamine or its pharmaceutically acceptable salt is administered by pulmonary route as a dry powder pharmaceutical formulation.
  • the invention provides a method of treatment depression in a subject in need thereof, wherein ketamine or its pharmaceutically acceptable salt is administered to a subject by pulmonary route as a dry powder pharmaceutical formulation.
  • FIG. 1 presents NGI deposition data for the composition of Example 1
  • FIG. 2 presents NGI deposition data for the composition of Example 2
  • FIG. 3 presents NGI deposition data for the composition of Example 3.
  • FIG. 4 presents NGI deposition data for the composition of Example 4.
  • FIG. 5 presents NGI deposition data for the composition of Example 5.
  • FIG. 6 presents NGI deposition data for the composition of Example 6
  • FIG. 7 shows esketamine plasma concentration vs time after administration of various single doses of dry powder composition of Example 2;
  • FIG. 8 shows esketamine plasma concentration vs time after administration of a sequence of single doses of dry powder composition of Example 2.
  • FIG. 9 presents adverse effect distribution after administration of dry powder composition of Example 2.
  • the object of the invention is a dry powder pharmaceutical composition comprising ketamine or its pharmaceutically acceptable salt as a medicine for use in a method of treatment of depression by pulmonary administration, i.e. administration via pulmonary route.
  • Another object of the invention is ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression, wherein ketamine or its pharmaceutically acceptable salt is administered by pulmonary route as a dry powder pharmaceutical formulation.
  • Another object of the invention is a method of treatment of depression in a subject in thereof, wherein ketamine or its pharmaceutically acceptable salt is administered to a subject by pulmonary route as a dry powder pharmaceutical formulation.
  • esketamine is self-administered pulmonary by a patient by inhalation of a dry powder esketamine composition or formulation in a sequence of administrations consisting of multiple single doses (inhalation events), such as at least 3 single doses, each inhalation event consisting of multiple puffs, such as 1, 2, 3 or 4 puffs, preferably in 3 or 4 puffs, said sequences being separated from each other by a break period without any inhalation (rest period).
  • such as sequence lasts at least 30 minutes, for example lasts 30 minutes, and includes 3 sequences of administration and break periods between are preferably equal, i.e. are 15 minutes break (rest) period.
  • esketamine is self-administered pulmonary by a patient by inhalation of a dry powder esketamine composition or formulation in a sequence lasting 30 minutes consisting of 3 single doses (inhalation events), each inhalation event consisting of 3 or 4 puffs, wherein each puff corresponds to esketamine nominal dose of 4 mg in the dry powder composition or formulation.
  • a dry powder esketamine composition or formulation in a sequence lasting 30 minutes consisting of 3 single doses (inhalation events), each inhalation event consisting of 3 or 4 puffs, wherein each puff corresponds to esketamine nominal dose of 4 mg in the dry powder composition or formulation.
  • Such a composition or formulation is described in Example 2 below.
  • a break period without any inhalation preferably there are two equal breaks lasting about 15 minutes, i.e.
  • ketamine encompasses racemic ketamine and its enantiomers esketamine and arketamine, both as a free base and pharmaceutically acceptable salts thereof.
  • ketamine is esketamine.
  • ketamine is racemic ketamine.
  • Preferred pharmaceutically acceptable ketamine salt is hydrochloride.
  • the composition of the invention comprises esketamine hydrochloride.
  • composition of the invention comprises racemic ketamine hydrochloride.
  • esketamine such as esketamine hydrochloride
  • a dry powder esketamine composition or formulation in a sequence lasting 30 minutes consisting of 3 single doses (inhalation events), each inhalation event consisting of 3 or 4 puffs, wherein each puff corresponds to esketamine nominal dose of 4 mg in the dry powder composition or formulation.
  • a composition or formulation is described in Example 2 below.
  • first single dose is administered at time 0
  • second single dose is administered after about 15 minutes
  • the third single dose is administered at 30 minute.
  • Such a sequence allows to obtain plasma concentration profile that provides plasma concentration infusion at the level having antidepressant effect, as known from prior art tests of intravenous infusions.
  • treatment-resistant or treatment refractory depression is well known in the art and means depression in patients not responding to at least two prior attempts of adequate antidepressive treatment using commonly known antidepressant therapies.
  • TRD treatment-resistant or treatment refractory depression
  • bipolar disorder is well known in the art and means a disorder that causes periods of depression and periods of abnormally elevated mood.
  • major depression is well known in the art and means a disorder characterized by at least two weeks of low mood that is present across most situations.
  • composition of the invention comprises from 2 mg to 100 mg of ketamine calculated as a free base per nominal unit dose.
  • the composition of the invention comprises from 2 mg to 60 mg of ketamine, especially 2 mg to 40 mg of ketamine, such as from 3 mg to 15 mg of ketamine, calculated as a free base, per nominal unit dose.
  • composition of the invention comprises further one or more additives selected from the group consisting of a carbohydrate bulking agent in the amount of 30 to 95% by weight and a stabilizing agent in the amount of 0.2
  • the composition comprises ketamine, especially esketamine hydrochloride, having median particle diameter d50 of 1-10 ⁇ m, such as 1-8 ⁇ m, especially 3 ⁇ m, d10 of 0.2-5 ⁇ m and d90 of 3-35 ⁇ m.
  • Median particle size d50 is a parameter obtained by laser diffraction technique with dry dispersion using Sympatec HELOS laser diffractometer attached with ASPIROS feeder.
  • raw ketamine especially esketamine hydrochloride, is dispersed with pressure 3.0 bar in total amount of 30 mg per sample.
  • composition is a dry powder formulation for administration using dry powder inhalers. Conventional and typical dry powder inhalers can be used for this purpose.
  • dry powder is known for a skilled person and should be understood in a manner conventional in the art as a solid mix of particles that is fluidized when the patient inhales after actuation of the inhaler device.
  • nominal unit dose in accordance with the invention relates to the ketamine dose as present (loaded) in the composition that is destined for a single administration.
  • the nominal unit dose can be a measured dose of the dry powder to be ready for the patient to take, contained in a single unit, such as a capsule or single compartment in a blister, or a dose to be taken from for delivery from the multi-dose dry powder reservoir.
  • mitted dose relates to the proportion of the nominal unit dose that exits/leaves the device after inhalation by a patient.
  • the dry powder pharmaceutical composition or formulation for use according to the invention may comprise further pharmaceutical excipients., i.e. one or more additives selected from the group consisting of a carbohydrate bulking agent (a carrier) in the amount of 30 to 95% by weight and a stabilizing agent in the amount of 0.2-3% by weight, with respect to the total weight of the composition.
  • a carbohydrate bulking agent a carrier
  • a stabilizing agent in the amount of 0.2-3% by weight
  • Suitable carbohydrate bulking agent can be lactose, D-mannitol, glucose monohydrate, trehalose, especially trehalose dihydrate, erythritol, dextrose, maltose, sorbitol or xylitol.
  • Especially convenient bulking agent is milled lactose, such as lactose monohydrate or anhydrous lactose, especially lactose monohydrate, having suitable granulometry.
  • Suitable granulometry is defined as having d50 30-200 ⁇ m (Sympatec HELOS) as the main coarse fraction (especially 80 ⁇ m).
  • lactose monohydrate commercial grades are Lactohale 200 (LH200), Lactohale 100 (LH100) and Lactohale 200LP.
  • LH200 Lactohale 200
  • LH100 Lactohale 100
  • Lactohale 200LP Lactohale 200LP
  • lactose grade most suitable for performance thereof. Such a selection is within common skills of a skilled person.
  • Typical amount of the bulking agent in the composition of the invention is 30-95% by weight, especially 30 to 80% by weight, with respect to the total weight of the composition.
  • compositions/additives include also a stabilizer (also called force control agent—FCA), i.e. a substance that reduces adhesion and cohesion.
  • a stabilizer also called force control agent—FCA
  • Suitable stabilizers are for example magnesium stearate, lecithin, and aminoacids, such as leucine.
  • Especially preferred stabilizer is magnesium stearate.
  • Stabilizer “disturbs” the weak binding forces between the small particles and thus helps to keep the particles separated, reduces self-adhesion of small particles and also adherence to other particles in the formulation if such other particles are present, reduces the adhesion to the inner surfaces of the inhaler, as well as improves rheological properties of powder—powder flowability.
  • the amount of the stabilizer in the composition of the invention is 0.2-3% by weight, especially 0.8% by weight, with respect to the total weight of the composition.
  • Composition or formulation for use according to the invention is prepared by blending in a high-shear mixer a bulking agent/carrier of suitable granulometry with a stabilizer, and then adding ketamine, especially esketamine hydrochloride, of suitable granulometry and again blending in a high-shear mixer.
  • ketamine especially esketamine hydrochloride, of suitable granulometry is co-processed (blended) with a stabilizer in a high-shear mixer, and then the bulking agent/carrier is added and again mixed in a high-shear mixer.
  • composition is a dry powder formulation for administration using dry powder inhalers. Conventional and typical dry powder inhalers can be used for this purpose.
  • the medicine for administration via pulmonary route is a blister with plurality of individual nominal unit doses premetered and individually sealed.
  • an inhaler is Diskus type inhaler.
  • the medicine for administration via pulmonary route is a capsule with a single nominal unit dose.
  • the medicine for administration of a single dose via pulmonary route is a multi-dose powder reservoir.
  • composition for use according to the invention provides emitted dose of at least 1.0 mg of ketamine calculated as a free base, corresponding to 1.2 mg of ketamine hydrochloride.
  • composition for use according to the invention provides the fraction of the dose delivered locally directly to the lungs that is at least 40%, such as from 40 to 50%, especially 40% to 60%, especially up to 85%, of the emitted unit dose.
  • Emitted dose is the portion of nominal unit dose that is emitted from the inhaler device and leaves the inhaler device as an aerosol and hence is available to the patient.
  • the uniform and stable high-dose ketamine, especially esketamine hydrochloride dry powder composition can be obtained that when administered by pulmonary route provides therapeutic ketamine level in the circulating blood of a patient, i.e. at least 50 to 100 ng/ml, such as 70 to 100 ng/ml, such as 70-80 ng/ml, such as about 100 ng/ml.
  • Therapeutic ketamine level relates to the level in the blood that is effective in the treatment of depression, especially major depressive disorder, such as treatment resistant or treatment-refractory depression, and may be dependent on the subject, gender, age, severity of the disease, the type of the inhaler, and may vary depending on whether ketamine is racemic ketamine or enantiomeric ketamine.
  • the fraction of the emitted dose delivered to the lungs is surprisingly high, in contrast with typical inhalation compositions wherein the standard is that only 15 to 20% of the emitted dose is delivered to the lungs.
  • the fraction of the emitted dose delivered locally directly to the lungs can be determined using well-known and conventional methods and assays. Such methods and assays include any of those described in European Pharmacopeia 9.0, Chapter 2.9.18, Preparations for inhalation; Aerodynamic assessment of fine particles for determination of Fine Particle Dose.
  • the Next Generation Pharmaceutical Impactor (NGI) (Ph. Eur. Apparatus E) can be used to assess and control the aerodynamic particle size distribution (APSD).
  • NGI apparatus is as presented in FIGS. 2.9.18.-12 and 2.9.18.-13 on page 333 of European Pharmacopeia 9.0.
  • Emitted dose and fine particle dose and fraction are strongly dependent on two factors i.e. on the formulation and on the device.
  • the resistance of a dry powder inhaler is an intrinsic value which depends on the design of the inhalation channel, the metering cup and the air inlets. DPIs can be classified into four resistance groups (low, medium, medium-high, high) with respect to the inhalation flow required to produce a pressure drop of 4 kPa. This value was chosen because it is the one recommended by pharmacopoeia for the in vitro characterization of the dose emitted from a DPI. Additionally for capsule-based DPIs can be limited by the powder retention in the capsule and device, which lead to reduction in the emitted dose.
  • Emitted dose testing is relatively straightforward.
  • the device is ‘fired’ into a sampling apparatus that enables the capture of the measured dose on a filter.
  • the aerodynamic particle size distribution of inhaled products is measured using the technique of multistage cascade impaction, here Next Generation Impactor (NGI).
  • NTI Next Generation Impactor
  • the collected quantity of active ingredient is determined further by HPLC analysis.
  • the inhalers are tested at a predetermined flow rate, and the pressure drop across the inhaler is 4.0 kPa in line with the Ph Eur.
  • Stages 1 to 7 and MOC Each stage is washed with appropriate diluent (extraction of drug substance).
  • NGI tray loaded with the cups on a Copley Gentle Rocker is gently shaken for 10 minutes.
  • Mouthpiece adapter Deposited inhalation powder on adapter is rinsed with appropriate diluent a volumetric flask and sonicated for 10 minutes.
  • Induction port Deposited inhalation powder from induction port is rinsed with appropriate diluent into a volumetric flask and sonicated for 10 minutes.
  • Preseparator Deposited inhalation powder from these component is rinsed with appropriate diluent into a volumetric flask and sonicated for 10 minutes. Finally collected samples from each stage of impactor are filtered analyzed by high-performance liquid chromatography
  • Composition of for use according to the invention has an appropriate ketamine, in particular esketamine hydrochloride pharmacokinetics profile that enables achievement of approximately 50 to 100 ng/ml of the ketamine plasma concentration over 40 minutes after pulmonary administration directly to the lungs by inhalation. Said plasma concentration corresponds to antidepressive effect. Maintaining this concentration over time mimics 40-minute intravenous infusion known to be effective in depression and well-tolerated.
  • a sum of lactose monohydrate and magnesium stearate are sieved through 0.25 mm mesh and mixed in high-shear mixer for 3 minutes. Obtained mixture is sieved with active substance through 0.5 mm mesh and mixed in high-shear mixer for 5 minutes.
  • antistatic PE bags are used during the process.
  • Vacuum-drum technology dose forming process is used for blister filling.
  • the blister cavity is in volume range of 15 to 45 mm 3 (especially ca. 30 mm 3 ).
  • Powder which is filled into cavity is in amount of 10-30 mg (especially 23 mg).
  • Capsules to be filled are placed in the sockets dosed ends down. Powder is discharged from the dosator and comes directly to the capsules. The powder with which the capsules are to be filled is placed in the dosator, may be tamped and discharged into the capsules.
  • capsule filling device During the process parameters of capsule filling device are:
  • compositions of Examples 1, 2 and 3 of the invention have been tested using the Next Generation Pharmaceutical Impactor (NGI) (Ph. Eur. Apparatus E) in accordance with the procedure for powder inhalers.
  • NMI Next Generation Pharmaceutical Impactor
  • ISM Impactor sized mass
  • MMAD mass median aerodynamic diameter. Defined as the diameter at which 50% of the particles by mass are larger and 50% are smaller.
  • the obtained results showed a product with expected quality attributes.
  • composition of the invention demonstrated appropriate homogeneity and a very high level of fine particle fractions, with:
  • compositions has been prepared in accordance with the above general procedure in the scale of 0.9 kg.
  • compositions of Examples 4, 5 and 6 of the invention have been tested using the Next Generation Pharmaceutical Impactor (NGI) (Ph. Eur. Apparatus E) in accordance with the procedure for powder inhalers.
  • NMI Next Generation Pharmaceutical Impactor
  • the obtained results showed a product with expected quality attributes.
  • the invented formulation demonstrated appropriate homogeneity and a very high level of fine particle fractions, with:
  • the dry powder pharmaceutical composition of the invention provided emitted esketamine hydrochloride dose at the level up to 97%, such as up to 85% of the nominal dose and at least 40% of fine particle fraction (fraction delivered to the lungs) for emitted esketamine dose.
  • Esketamine hydrochloride dry powder formulation of Example 2 was administered to healthy volunteers pulmonary, i.e. directly to the lungs using dry powder inhaler (DPI) (by self-administration).
  • DPI dry powder inhaler
  • One puff of dry powder formulation contained 4.6 mg of esketamine hydrochloride, corresponding to 4 mg of esketamine free base and excipients 18.22 mg of lactose monohydrate and 0.18 mg of magnesium stearate.
  • a single dose was an inhalation events consisting of 1 to 6 puffs, i.e. 4 to 24 mg of esketamine free base nominal dose.
  • part A of the study designed as a one-centre single ascending dose, the medicine was delivered in a single dose once daily (up to 6 consecutive puffs) to 18 healthy volunteer subjects. Subjects were divided into 6 cohorts, cohorts receiving 1, 2, 3, 4, 5 or 6 puffs in a single doses (inhalation events), respectively. Collection of blood samples for determination of esketamine and esnorketamine concentration and calculation of pharmacokinetic parameters was performed for up 24 hours following the start of the test.
  • the aim of the study was to determine the amount of puffs needed to obtain plasma concentration similar to that sufficient to achieve antidepressant effect as for 0.20 mg/kg 40 minutes intravenous infusion. It can be predicted on the basis of literature data that this corresponds to concentration at 40 min of infusion between about 60 to 100 ng/ml. It was also the aim to determine the number of puffs that allow to avoid a sharp peak of plasma concentration that is considered an important factor inducing adverse psychomimetic and dissociative effects.
  • FIG. 7 shows esketamine plasma concentration over time after administration of various single doses of dry powder composition of Example 2.
  • the number of puffs that allows to obtain plasma esketamine concentration sufficient for antidepressant effect and without sharp peak of said concentration was determined to be 1 to 4 puffs, corresponding to 4 to 16 mg of esketamine free base nominal dose.
  • Example 2 In part B of the study the composition of Example 2 was administered to 12 healthy volunteer subjects divided into 4 cohorts in four different single doses each cohort (i.e. each single dose consisting of 1, 2, 3 or 4 puffs, respectively) in one day in the administration sequence consisting of three administrations of single dose (inhalation event) in the period of 30 minutes, Between inhalation events there were 15 minutes break periods, i.e. first single dose was administered at 0 min., second single dose was administered at 15 min, and third single dose was administered at 30 min.
  • first single dose was administered at 0 min.
  • second single dose was administered at 15 min
  • third single dose was administered at 30 min.
  • Part B The aim of Part B was to investigate pharmacokinetic properties of esketamine following different dosing schemes in healthy subjects and determine the scheme that enables achievement of the appropriate plasma concentration over time to mimic the 40-minute intravenous infusion (part B),
  • FIG. 8 shows esketamine plasma concentration over time after administration of various single doses of dry powder composition of Example 2 in a sequence of 3 administrations of single doses during 30 minutes.
  • FIG. 8 shows also (the area between two bold black lines) a simulation of esketamine plasma concentration after 0.2 mg/kg 40 minutes i.v. infusion.
  • sequence of administration of 3 single doses consisting of 3 or 4 puffs allowed to obtain plasma concentration profile mimicking quite well esketamine intravenous infusion at the level corresponding to antidepressant effect.
  • Plasma concentration profile is quite smooth, consistent with a target profile and safe for chronic administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
US16/958,965 2017-12-29 2018-09-28 Dry powder ketamine composition for use in the treatment of depression by pulmonary administration Pending US20200337999A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17461651.6A EP3505157B1 (en) 2017-12-29 2017-12-29 Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
PCT/EP2018/076394 WO2019129397A1 (en) 2017-12-29 2018-09-28 Dry powder ketamine composition for use in the treatment of depression by pulmonary administration

Publications (1)

Publication Number Publication Date
US20200337999A1 true US20200337999A1 (en) 2020-10-29

Family

ID=60915417

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/958,965 Pending US20200337999A1 (en) 2017-12-29 2018-09-28 Dry powder ketamine composition for use in the treatment of depression by pulmonary administration

Country Status (16)

Country Link
US (1) US20200337999A1 (es)
EP (2) EP3505157B1 (es)
JP (1) JP7315556B2 (es)
KR (1) KR20200105857A (es)
CN (1) CN111818912A (es)
AU (1) AU2018395791A1 (es)
BR (1) BR112020013282A2 (es)
CA (1) CA3087090A1 (es)
DK (2) DK3505157T3 (es)
EA (1) EA202091618A1 (es)
ES (2) ES2907692T3 (es)
HU (2) HUE058320T2 (es)
MX (1) MX2020006900A (es)
PL (2) PL3505157T3 (es)
PT (2) PT3505157T (es)
WO (1) WO2019129397A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210353560A1 (en) * 2018-09-28 2021-11-18 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045601A1 (en) * 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US20080132531A1 (en) * 2005-11-11 2008-06-05 Yaupon Therapeutics, Inc. Synergistic combinations of norketamine and opioid analgesics
US20150050350A1 (en) * 2000-04-17 2015-02-19 Vectura Limited Pharmaceutical formulations for dry powder inhalers
US20150328159A1 (en) * 2009-05-12 2015-11-19 Innovata Limited Composition
US20170151191A1 (en) * 2006-03-22 2017-06-01 Icahn School Of Medicine At Mount Sinai Intranasal administration of ketamine to treat depression
US20210353560A1 (en) * 2018-09-28 2021-11-18 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025925A1 (en) * 1995-02-24 1996-08-29 Weg Stuart L Nasal and ocular administration of ketamine to manage pain and for detoxification
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
CN104519878A (zh) 2012-03-12 2015-04-15 詹森药业有限公司 用于治疗顽固性或难治性抑郁症的艾氯胺酮
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
SG10201802104QA (en) 2013-03-15 2018-05-30 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
US20140275277A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
CN105324106A (zh) 2013-04-01 2016-02-10 普马特里克斯营业公司 噻托铵干粉
WO2016057712A1 (en) 2014-10-07 2016-04-14 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150050350A1 (en) * 2000-04-17 2015-02-19 Vectura Limited Pharmaceutical formulations for dry powder inhalers
WO2004045601A1 (en) * 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US20080132531A1 (en) * 2005-11-11 2008-06-05 Yaupon Therapeutics, Inc. Synergistic combinations of norketamine and opioid analgesics
US20170151191A1 (en) * 2006-03-22 2017-06-01 Icahn School Of Medicine At Mount Sinai Intranasal administration of ketamine to treat depression
US20150328159A1 (en) * 2009-05-12 2015-11-19 Innovata Limited Composition
US20210353560A1 (en) * 2018-09-28 2021-11-18 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Myers, The science guiding selection of an aerosol delivery device, Respiratory Care. November 2013 Vol. 58, No. 11. (Year: 2013) *
Pfizer, Material safety data sheet- (S)-(+)-Ketamine hydrochloride, Obtained from the internet. (Year: 2008) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210353560A1 (en) * 2018-09-28 2021-11-18 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration
US11925607B2 (en) * 2018-09-28 2024-03-12 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration

Also Published As

Publication number Publication date
MX2020006900A (es) 2020-11-09
PL3505157T3 (pl) 2022-04-11
BR112020013282A2 (pt) 2020-12-01
EA202091618A1 (ru) 2021-03-17
PL3731815T3 (pl) 2022-04-11
EP3731815A1 (en) 2020-11-04
WO2019129397A1 (en) 2019-07-04
ES2907692T3 (es) 2022-04-26
HUE058099T2 (hu) 2022-07-28
ES2907781T3 (es) 2022-04-26
HUE058320T2 (hu) 2022-07-28
DK3731815T3 (da) 2022-02-28
CN111818912A (zh) 2020-10-23
DK3505157T3 (da) 2022-02-28
PT3505157T (pt) 2022-02-18
EP3505157B1 (en) 2021-12-08
CA3087090A1 (en) 2019-07-04
JP2021510682A (ja) 2021-04-30
KR20200105857A (ko) 2020-09-09
AU2018395791A1 (en) 2020-07-16
EP3731815B1 (en) 2021-12-08
PT3731815T (pt) 2022-02-15
EP3505157A1 (en) 2019-07-03
JP7315556B2 (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
US20100178331A1 (en) Preparation for transnasal application
ES2775606T3 (es) Furoato de fluticasona en el tratamiento de la EPOC
KR20180104197A (ko) 아베디테롤의 신규한 투약 형태 및 제형
US11925607B2 (en) Ketamine composition for use in a method of treatment of depression by pulmonary administration
EP3731815B1 (en) Dry powder ketamine composition for use in the treatment of depression by pulmonary administration
CN107205936B (zh) 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物
US20220230723A1 (en) Electronically Supervised Administration of a Pharmaceutical Composition
EA044969B1 (ru) Композиция кетамина для применения в способе лечения депрессии путём ингаляционного введения
AU2013100007A4 (en) System for treating chronic obstructive pulmonary disease
US20220226586A1 (en) An Inhaler For Electronically Supervised Parenteral Administration of a Pharmaceutical Composition
AU2013100008B4 (en) Inhalable formulations of glycopyrronium bromide
AU2013100009B4 (en) Treatment of chronic obstructive pulmonary disease
WO2022123607A1 (en) Pharmaceutical formulations of esketamine

Legal Events

Date Code Title Description
AS Assignment

Owner name: CELON PHARMA S.A., POLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WIECZOREK, MACIEJ;TRATKIEWICZ, EWA;PERKO, PRZEMYSLAW;REEL/FRAME:053075/0573

Effective date: 20200626

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER